

BLADDER CANCER PROGRAM OVERVIEW

MSK's urologic cancer program is recognized as one of the world's finest,



ranked fifth out of 51 top-scoring hospitals for urology in U.S. News & World Report.

We provide patients with:

- access to world leaders in bladder cancer surgery, medical oncology, radiation oncology, and nursing
- the benefit of seeing several dedicated bladder cancer specialists on one day, at one location
- the latest minimally invasive, image-guided techniques for diagnosis and treatment
- bladder preservation in selected patients with invasive cancer
- an individualized treatment plan, comprehensive risk assessment, and long-term surveillance program
- access to innovative clinical trials of new therapies, surgical techniques, and advanced technologies not available at other hospitals
- genomic sequencing for all patients to look for actionable mutations

LOCATIONS

Many of MSK's specialists are centrally located in **Manhattan**. There are also MSK's regional outpatient locations:

- MSK Basking Ridge, New Jersey
- MSK Bergen, New Jersey
- MSK Monmouth, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York
- MSK Westchester, New York

REFER A PATIENT

Contact the Physician Access Service directly at

800-525-2225

MSK has insurance contracts with most major health plans in the New York tristate area.

Our Team Leaders

Jonathan Rosenberg, MD
Chief, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz Chair

Victor Reuter, MD
Vice Chair, Department of Pathology; Director, Genitourinary Pathology; Director, Genitourinary Pathology Fellowship; Director, Pathology Core Facility

Alvin Goh, MD
Director, Robotic Urologic Surgery Technology and Education

Dean Bajorin, MD
Frederick R. Adler Senior Faculty Chair

Bernard Bochner, MD, FACS
Sir Murray F. Brennan Chair in Surgery

Guido Dalbagni, MD
Urologic Surgeon

S. Machele Donat, MD, FACS
Urologic Surgeon

Harry Herr, MD, FACS
Urologic Surgeon

David Solit, MD
Geoffrey Beene Chair; Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology

Sign up for OncoNotes, MSK's clinical updates newsletter.

Go to MSKCC.org, click on the **For Health Professionals** section, and choose "Sign Up for Our E-newsletter."



Memorial Sloan Kettering
Cancer Center




Bladder Cancer Program



Memorial Sloan Kettering
Cancer Center

WHY CHOOSE MSK FOR BLADDER CANCER CARE?



By the Numbers

200

cystectomies performed per year
and 1,200 cystoscopies and
transurethral resections of bladder
tumors performed in 2017

7
bladder
cancer
surgeons



7
locations



Expertise

- Our surgeons are among the most experienced in the world at performing **radical cystectomy and have pioneered pelvic lymph node dissection** to reduce the risk of cancer recurrence.
- We have extensive experience with successful **urinary tract reconstruction** in men and women to preserve natural voiding.
- We routinely employ **sexual function-sparing surgery** to help patients maintain intimacy after bladder removal surgery.

Leadership

- Our surgeons participate in establishing the **latest national guidelines** for surgery, reconstruction, and surgical care.
- We completed the only properly powered randomized clinical study investigating the use of **robotic technology for bladder removal**.
- We have **more than 23 bladder cancer clinical trials underway** for a range of targeted therapies, immunotherapies, and novel surgical approaches. Our oncologists are leading many of the latest national trials for cutting-edge targeted chemotherapies and immunotherapies.
- Working with our **world-class geneticists**, we are leading the genetic investigations that will shape the future of treatment for urothelial tumors.

Advanced Technologies

- MSK is one of a few centers in the world providing **robotic cystectomy and completely intracorporeal bladder reconstruction in the same operation** for selected cases.
- We routinely utilize **MSK-IMPACT™**, a genome-sequencing test developed at MSK that quickly determines if tumors have actionable mutations using available targeted therapies or if patients may benefit from clinical trials.
- We offer **neoadjuvant chemotherapy** targeted to the genomic profile of patients' individual cancers.